Literature DB >> 2538179

Paf-induced release of spasmogens from guinea-pig lungs.

S Jancar1, P Thériault, M Lauzière, P Braquet, P Sirois.   

Abstract

1. The injection of platelet activating factor (Paf; 250 ng), leukotriene B4 (LTB4; 50 ng) and leukotriene D4 (LTD4; 10 ng) elicited contractions of strips of guinea-pig trachea, bronchus and lung parenchyma. 2. When the effluent of perfused guinea-pig lungs was superfused over strips of guinea-pig trachea, bronchus and parenchyma, the intra-arterial injection of Paf (250 ng) caused the release of spasmogen(s) which contracted all three tissues. 3. The infusion of indomethacin (10 micrograms ml-1) into the pulmonary artery and over the assay tissues inhibited the responses of the tissues to the effluent of the lungs stimulated by Paf (250 ng) and LTB4 (50 ng). However, treating only the assay tissues with indomethacin (10 micrograms ml-1) did not block the contractile responses to the effluent of the lungs stimulated with LTB4 or Paf. stimulated with Paf. 4. Pretreatment of the lungs with indomethacin (10 micrograms ml-1) or aspirin (30 micrograms ml-1) for 30 min, washing them out and suspending them over the assay tissues did not block the release of spasmogens elicited by Paf but appeared to inhibit the release of cyclo-oxygenase products. 5. The infusion of two lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA; 1 microgram ml-1) and L-655,240 (1 microgram ml-1), into the pulmonary artery completely blocked the release of spasmogen(s) from the perfused lungs. 6. The slow reacting substance of anaphylaxis (SRS-A) antagonist, FPL-55712 (10 ng ml-1), did not block the responses of the tissues to the spasmogen(s) release by Paf. 7. The infusion of the Paf antagonist BN-52021 (30 micrograms ml-1) into the pulmonary artery completely abolished the release of spasmogen(s) induced by Paf. 8. These data suggest that a lipoxygenase product, possibly LTB4, could be responsible for the spasmogenic activity released by the lungs following Paf stimulation. Cyclo-oxygenase products released following Paf stimulation appear to result from the initial LTB4 generation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538179      PMCID: PMC1854309          DOI: 10.1111/j.1476-5381.1989.tb11795.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

Review 1.  PAF-acether today--relevance for acute experimental anaphylaxis.

Authors:  B B Vargaftig; P G Braquet
Journal:  Br Med Bull       Date:  1987-04       Impact factor: 4.291

2.  The action of leukotriene B4 (LTB4) on the lung.

Authors:  P Sirois; P Borgeat; A Jeanson; S Roy; G Girard
Journal:  Prostaglandins Med       Date:  1980-12

3.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.

Authors:  B B Vargaftig; J Lefort; M Chignard; J Benveniste
Journal:  Eur J Pharmacol       Date:  1980-07-25       Impact factor: 4.432

4.  Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether).

Authors:  B B Vargaftig; J Lefort; F Wal; M Chignard; M C Medeiros
Journal:  Eur J Pharmacol       Date:  1982-08-27       Impact factor: 4.432

5.  Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes.

Authors:  A H Lin; D R Morton; R R Gorman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

6.  Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig.

Authors:  J Bonnet; D Thibaudeau; P Bessin
Journal:  Prostaglandins       Date:  1983-09

7.  Evidence for a mediator role of thromboxane A2 in the myotropic action of leukotriene B4 (LTB4) on the guinea-pig lung.

Authors:  P Sirois; S Roy; P Borgeat; S Picard; P Vallerand
Journal:  Prostaglandins Leukot Med       Date:  1982-02

8.  Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution.

Authors:  Y Hamasaki; M Mojarad; T Saga; H H Tai; S I Said
Journal:  Am Rev Respir Dis       Date:  1984-05

9.  Guinea pig bronchus as a model for icosanoid studies.

Authors:  P Sirois; S Prié; P Thériault; G Rouleau; M Lauzière
Journal:  Inflammation       Date:  1987-12       Impact factor: 4.092

10.  Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine.

Authors:  F H Chilton; J T O'Flaherty; C E Walsh; M J Thomas; R L Wykle; L R DeChatelet; B M Waite
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

View more
  7 in total

1.  Platelet-activating factor relaxes ferret tracheal smooth muscle and reduces transepithelial potential difference in vitro.

Authors:  S E Webber; T Morikawa; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Pharmacological modulation of endothelin-induced contraction of guinea-pig isolated airways and thromboxane release.

Authors:  J G Filep; B Battistini; P Sirois
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

4.  Effects of PAF on excitatory neuro-effector transmission in dog airways.

Authors:  K Tashiro; Z Xie; Y Ito
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

5.  Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites.

Authors:  L Argiolas; F Fabi; P del Basso
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

6.  Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man.

Authors:  D A Spencer; J M Evans; S E Green; P J Piper; J F Costello
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

7.  Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor.

Authors:  J Spring; S R Johnston; J Seale; P W Ind
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.